Scheduling, administration, biomarkers, and practical guidance.
Maximum 24-month treatment window
Maximum 24-month treatment window
Oral formulation; dose escalation per tolerance
Research chemical status; monitor glucose and insulin sensitivity
Essential throughout entire protocol duration
Critical to preserve gains; discontinuation without transition causes rebound bone loss
Allows monitoring for orthostatic hypotension during waking hours; aligns with physiological cortisol peak
Tachycardia risk within 15 min and up to 6 h post-dose is best monitored during the day
GH secretagogue; aligns with nocturnal GH pulse to amplify physiological release pattern
GH secretagogue; bedtime dosing synergizes with natural GH pulsatility
Calcium absorption is improved with food; spacing from PTH analog avoids blunting the anabolic signal